However, the response rates to PD-1/PD-L1 inhibitors in urothelial carcinoma are unsatisfactory, indicating the presence of additional immune-inhibitory pathways other than the PD-1/PD-L1 pathway that contribute to tumor immune evasion. This evidence concerns the gene CD274 and urothelial carcinoma.